Desensitized living donor kidney transplantation

Desensitized living donor kidney transplantation has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest story, Oct 30, 2026: “Incompatible living-donor kidney transplants tied to longer survival”.

Exposure

1 paper studies it4 findingsUpdated

1 new paper in 30 daysSee all 1

“10-year patient survival was significantly higher in desensitized LDKT compared with the CWS group (86.3% vs. 56.8%, P < 0.001).”
Survival benefit of ABO- or HLA-incompatible living donor kidney transplantation compared with waiting for deceased donor kidney transplantation in elderly patients: a retrospective cohort studyInternational journal of surgery (London, England)2026doi:10.1097/js9.0000000000005608

1 of its findings points the other way.

  • 1 lab in 1 country
  • 1 finding against
  • Humans1

What did studies of Desensitized living donor kidney transplantation find?

2

Studies of Desensitized living donor kidney transplantation measured 2 outcomes; the most studied are acute rejection (1 study) and patient survival (1).

Acute rejection

no changein humans1

1 study
  1. Desensitized living donor kidney transplantation was not clearly linked with acute rejection in humans (ESKD; compared with deceased donor kidney transplantation; biopsy-proven rejection) (22.9% vs. 29.6%).

    “with similar rates of biopsy-proven acute rejection (22.9% vs. 29.6%, P = 0.28).”

    HumansESKD; compared with deceased donor kidney transplantation; biopsy-proven rejectionABO-incompatible or HLA-incompatiblekidney

    Incompatible living-donor kidney transplants tied to longer survival

    International journal of surgery (London, England)

More on Acute rejection

Patient survival

no changein humans1HR 0.99

1 study
  1. Desensitized living donor kidney transplantation was not clearly linked with patient survival in humans (ESKD; compared with deceased donor kidney transplantation) (HR 0.99, 95% CI 0.42–2.37).

    “Patient survival was comparable between desensitized LDKT and DDKT (HR, 0.99; 95% CI, 0.42–2.37; P > 0.99).”

    HumansESKD; compared with deceased donor kidney transplantationABO-incompatible or HLA-incompatible

    Incompatible living-donor kidney transplants tied to longer survival

    International journal of surgery (London, England)

What is Desensitized living donor kidney transplantation linked with?

2

Studies link Desensitized living donor kidney transplantation with 2 measures, most often graft survival (1 study) and patient survival (1).

Graft survival

upin humans1

1 study
  1. Desensitized living donor kidney transplantation is associated with graft survival in humans (ESKD; compared with deceased donor kidney transplantation) (93.9% vs. 78.2%).

    “Five-year graft survival was higher in desensitized LDKT than DDKT (93.9% vs. 78.2%, P = 0.009)”

    HumansESKD; compared with deceased donor kidney transplantationABO-incompatible or HLA-incompatiblekidney5 years

    Incompatible living-donor kidney transplants tied to longer survival

    International journal of surgery (London, England)

Patient survival

upin humans1

1 study
  1. Desensitized living donor kidney transplantation is associated with patient survival in humans (ESKD; propensity score-matched comparison with conventional waitlisting strategy) (86.3% vs. 56.8%).

    “10-year patient survival was significantly higher in desensitized LDKT compared with the CWS group (86.3% vs. 56.8%, P < 0.001).”

    HumansESKD; propensity score-matched comparison with conventional waitlisting strategyABO-incompatible or HLA-incompatible10 years

    Incompatible living-donor kidney transplants tied to longer survival

    International journal of surgery (London, England)

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 1Oct 2026: 0Nov 2026: 01 paper in 12 months
International Journal of Surgery

Incompatible living-donor kidney transplants tied to longer survival

Ten-year survival was 86.3% after incompatible living-donor transplants versus 56.8% with standard waitlist care in matched patients aged 60 or older.Ten-year survival was 86.3% after incompatible living-donor transplants versus 56.8% with standard waitlist care in matched patients aged 60 or older.

Cohort · 1,819 peopleKidney